Big Pharma

President Donald Trump‘s $3.3 trillion domestic agenda bill, passed by House Republicans on Thursday, includes a significant but little-noticed victory for pharmaceutical companies that will cost taxpayers nearly $5 billion over the next decade. What Happened: The legislation expands...

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happened: The clash, unfolding as of Friday, has reignited discussions on Pharmacy Benefit Managers (...

Jim Cramer has raised concerns over the constitutionality of recent drug price controls, urging pharmaceutical companies to seek an injunction. What Happened:  CNBC’s Mad Money host, Cramer, in a post on X on Monday, argued that, unlike tariffs, drug price controls fall under the...

Mark Cuban, the billionaire entrepreneur, challenged Trump-supporter and political activist Charlie Kirk‘s stance on high drug prices, asserting that Pharmacy Benefit Managers (PBMs) are the main culprits, not Big Pharma. What Happened: Cuban criticized Kirk’s focus on Big...

Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, addressed a wide range of medical-related topics on Wednesday during a confirmation hearing with the Senate Finance Committee. While Kennedy’s tone in each back-and-forth varied, depending on the senator, it was...

In states where both medical and recreational marijuana are legal, patients are filling fewer prescriptions for medications commonly used to treat anxiety, according to a recent study published in JAMA Network Open. The findings consistently showed that increased access to marijuana correlates with...

Actor and cannabis advocate Jim Belushi took the stage at the recent Benzinga Cannabis Capital Conference in Chicago to share his passionate views on the food and pharmaceutical industries, cannabis' healing potential and his frustration with media narratives around the plant. Belushi, well-known...

“We've seen this movie before,” Al Harrington says in an exclusive interview with Benzinga Cannabis, displaying the conviction of someone who's lived through the consequences of history. The former NBA player turned cannabis entrepreneur knows all too well how power structures have...

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) plans to land $4 billion in revenue by 2027. The company is targeting an adjusted operating margin of low-to-mid 40%’s (starting at 40% in 2026). The new structure, announced at an investor event Wednesday, covers three key business units. They...

A recent report from the U.S. Federal Trade Commission (FTC) has brought attention to the substantial influence of pharmacy benefit managers (PBMs) on drug pricing due to market consolidation. This situation raises important questions about the future of the cannabis industry, particularly in the...

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This growth would be primarily fueled by the expansion of adult-use markets and adoption of new licensed and regulated markets, both medical and...

On Thursday, Merck & Co Inc (NYSE: MRK) topped estimates with its fourth quarter revenue and adjusted earnings fueled by its blockbuster cancer drug Keytruda, along with HPV prevention vaccine Gardasil. However, Merck still recorded a net quarterly loss due to...

As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall health of the planet that is only our home. This technology is being developed with the aim to reduce...

When it comes to Big Pharma, Japan’s Takeda Pharmaceutical Co Ltd (NYSE: TAK) is a conservative play that could prove to be a big winner given its cheap valuation and suite of new drugs that portend to dominate in treating niche illnesses. Takeda Pharma is Japan’s largest pharmaceutical...

The announcement last week by the department of Health and Human Services (HHS) that it is now recommending the rescheduling of cannabis from schedule I to III, marks a significant inflection point for federal cannabis reform. The timing of the Drug Enforcement Agency (DEA...